ZW25 is more effective than trastuzumab in binding to the tumor cells, inhibiting cell growth, receptor internalization, and downregulating HER2 expression in various HER2-expressing tumors, including HER2+ and HER2-low breast cancer [46,47]. Here, ERBB2 is linked to breast carcinoma.